The team that funded and led Vicept Therapeutics Inc. prior to its acquisition by Allergan Inc. last year has reunited for a fresh endeavor. Newly formed dermatology start-up Aclaris Therapeutics Inc. announced its $21 million Series A funding Oct. 24, revealing support from the same three venture capital firms that backed Vicept.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?